Anti-aging drugs improve glucose metabolism

Image source: pixabay

A study by the University of Washington School of Medicine in the United States showed that natural compounds that have been previously proven to delay aging in mice and improve metabolic health also have relevant clinical effects on humans.

A small clinical trial for postmenopausal women with prediabetes showed that compound nicotinamide mononucleotide (NMN) improves the ability of skeletal muscle to take up glucose, which is usually abnormal in patients with obesity, prediabetes or type 2 diabetes of.

Researchers conducted clinical trials on 25 postmenopausal women with prediabetes (blood sugar higher than normal but not yet diagnosed as diabetes) because previous studies on mice showed that NMN has the greatest impact on female mice.

NMN is involved in the synthesis of nicotinamide adenine dinucleotide (NAD), an important compound produced by all cells.

Although there is a lack of evidence that NMN has clinical benefits in humans, many people in the United States and around the world are now taking NMN.

The study's co-author, Shin-ichiro Imai, a professor of developmental biology and medicine who first reported that NMN is beneficial to mice, said: "This is a step in the development of anti-aging interventions, but more research is needed to fully understand the observations in human skeletal muscle.

Insulin promotes the uptake and storage of glucose in the muscles, so people who are resistant to insulin have an increased risk of developing type 2 diabetes.

Related paper information: org/10.